Home Global News Stocks News Updates: aTyr Pharma, Inc. (NASDAQ: LIFE)

Stocks News Updates: aTyr Pharma, Inc. (NASDAQ: LIFE)

120
1
SHARE

aTyr Pharma, Inc. (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat patients suffering from rare, severe, immune-mediated diseases, in addition to a variety of cancers, recently declared operating consequences for the 3rd-quarter finished September 30, 2K17.
3rd-Quarter 2K17 Financial Results:
Research and development costs were $7.10M and $10.40M for the 3-months finished September 30, 2K17 and 2K16, respectively. The decline of $3.30M was due mainly to a $2.20M decline related to manufacturing costs incurred in support of Resolaris and a $1.80M decline as a result of the completion of clinical trials related to Resolaris. The decline was partially offset by a $0.30M incline related to discovery research hard works, a $0.20M incline in iMod.Fc research and non-clinical development costs and $0.20M incline related to ORCA research activities.
General and administrative costs remained relatively consistent at $3.70M as contrast to $3.50M for the 3-months finished September 30, 2K17 and 2K16, respectively.
Year-to-Date 2K17 Financial Results:
Research and development costs were $24.80M and $33.70M for the 9-months finished September 30, 2K17 and 2K16, respectively. The decline of $8.90M was due mainly to a $6.50M decline related to manufacturing costs incurred in support of Resolaris, a $4.00M decline as a result of the completion of clinical trials related to Resolaris, a $0.30M decline in discovery projects, and a $0.30M decline in non-cash stock-based compensation. The decline was partially offset by a $1.10M incline related to research and non-clinical development costs incurred for iMod.Fc, and a $1.10M incline related to ORCA research activities.
General and administrative costs were $11.20M and $11.70M for the 9-months finished September 30, 2K17 and 2K16, respectively. The decline of $0.50M was mainly because of a decline in professional fees.
Financial Guidance:
As of September 30, 2K17, aTyr had $90.40M in cash, cash equivalents and investments and 41.10M shares of common stock outstanding on an if-converted basis (includes 29.70M shares of common stock and 11.40M shares of common stock if converted from Class X Preferred stock).
aTyr anticipates that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into the middle of 2k19.

Loading...

Amit Gola is Newspaper Head and Photographer. He is always motivated and passionate for his work and always try to give his best. He always try to learn new things.